Reversible resistance induced by FLT3 inhibition: A novel resistance mechanism in mutant FLT3-Expressing cells

PLoS ONE

Volumn 6, Issue 9, 2011, Pages

  Weisberg, Ellen ^a   Ray, Arghya ^a   Nelson, Erik ^a   Adamia, Sophia ^a   Barrett, Rosemary ^a   Sattler, Martin ^a   Zhang, Chengsheng ^a   Daley, John F ^a   Frank, David ^a   Fox, Edward ^a   Griffin, James D ^a  

^a DANA FARBER CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADENOSINE TRIPHOSPHATASE INHIBITOR; CD135 ANTIGEN; CYCLOHEXIMIDE; FLT3 LIGAND; HG 78501; MESSENGER RNA; MIDOSTAURIN; UNCLASSIFIED DRUG; DRUG DERIVATIVE; FLT3 PROTEIN, HUMAN; HG 7 85 01 COMPOUND; HG-7-85-01 COMPOUND; PIPERAZINE DERIVATIVE; PROTEIN KINASE INHIBITOR; STAUROSPORINE; THIAZOLE DERIVATIVE; TYROSINE;

ARTICLE; CELL SURFACE; CONTROLLED STUDY; DRUG MECHANISM; DRUG RESISTANCE; ENZYME ACTIVITY; FLOW CYTOMETRY; FLT3 GENE; GENE; GENE AMPLIFICATION; GENE EXPRESSION; GENE MUTATION; GENE OVEREXPRESSION; HALF LIFE TIME; HUMAN; HUMAN CELL; IMMUNOBLOTTING; IMMUNOPRECIPITATION; MOLECULAR DYNAMICS; POINT MUTATION; PROTEIN DOMAIN; PROTEIN EXPRESSION; PROTEIN METABOLISM; PROTEIN PHOSPHORYLATION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SIGNAL TRANSDUCTION; ACUTE GRANULOCYTIC LEUKEMIA; CELL PROLIFERATION; CHEMISTRY; DRUG ANTAGONISM; DRUG EFFECT; ENZYME STABILITY; GENE EXPRESSION REGULATION; GENETICS; METABOLISM; MUTATION; PATHOLOGY; PHOSPHORYLATION; TUMOR CELL LINE; UPREGULATION;

CELL LINE, TUMOR; CELL PROLIFERATION; DRUG RESISTANCE, NEOPLASM; ENZYME STABILITY; FMS-LIKE TYROSINE KINASE 3; GENE EXPRESSION REGULATION, NEOPLASTIC; HALF-LIFE; HUMANS; LEUKEMIA, MYELOID, ACUTE; MUTATION; PHOSPHORYLATION; PIPERAZINES; PROTEIN KINASE INHIBITORS; RNA, MESSENGER; SIGNAL TRANSDUCTION; STAUROSPORINE; THIAZOLES; TYROSINE; UP-REGULATION;

EID: 80053280767     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0025351     Document Type: Article

References (44)

1. Stirewalt DL, Radich JP, (2003) The role of FLT3 in hematopoeitic malignancies. Nat Rev Cancer 3: 650-665.
2. Nakao M, Yokota S, Iwai T, Kaneko H, Horiike S, et al. (1996) Internal tandem duplication of the FLT3 gene found in acute myeloid leukemia. Leukemia 10: 1911-1918.
3. Horiike S, Yokota S, Nakao M, Iwai T, Sasai Y, et al. (1997) Tandem duplications of the FLT3 receptor gene are associated with leukemic transformation of myelodysplasia. Leukemia 11: 1442-1446.
4. Kiyoi H, Towatari M, Yokota S, Hamaguchi M, Ohno R, et al. (1998) Internal tandem duplication of the FLT3 gene is a novel modality of elongation mutation which causes constitutive activation of the product. Leukemia 12: 1333-1337.
5. Kondo M, Horibe K, Takahashi Y, Matsumoto K, Fukuda M, et al. (1999) Prognostic value of internal tandem duplication of the FLT3 gene in childhood acute myelogenous leukemia. Med Pediatr Oncol 33: 525-529.
6. Rombouts WJ, Blokland I, Lowenberg B, Ploemacher RE, (2000) Biological characteristics and prognosis of adult acute myeloid leukemia with internal tandem duplications in the FLT3 gene. Leukemia 14: 675-683.
7. Yamamoto Y, Kiyoi H, Nakano Y, Suzuki R, Kodera Y, et al. (2001) Activating mutation of D835 within the activation loop of FLT3 in human hematologic malignancies. Blood 97: 2434-2439.
8. Jiang J, Paez JG, Lee JC, Bo R, Stone RM, et al. (2004) Identifying and characterizing a novel activating mutation of the FLT3 tyrosine kinase in AML. Blood 104: 1855-1858.
9. Kindler T, Breitenbuecher F, Kasper S, Estey E, Giles F, et al. (2005) Identification of a novel activating mutation (Y842C) within the activation loop of FLT3 in patients with acute myeloid leukemia (AML). Blood 105: 335-340.
10. Reindl C, Bagrintseva K, Vempati S, Schnittger S, Ellwart JW, et al. (2006) Point mutations in the juxtamembrane domain of FLT3 define a new class of activating mutations in AML. Blood 107: 3700-3707.
11. Weisberg E, Boulton C, Kelly LM, Manley P, Fabbro D, et al. (2002) Inhibition of mutant FLT3 receptors in leukemia cells by the small molecule tyrosine kinase inhibitors PKC412. Cancer Cell 1: 433-443.
12. Stone RM, De Angelo J, Galinsky I, Estey E, Klimek V, et al. (2004) PKC412 FLT3 inhibitor therapy in AML: results of a phase II trial. Ann Hematol 83 (Suppl 1): S89-90.
13. Stone RM, DeAngelo DJ, Klimek V, Galinsky I, Estey E, et al. (2005) Patients with acute myeloid leukemia and an activating mutation in FLT3 respond to a small-molecule FLT3 tyrosine kinase inhibitor, PKC412. Blood 105: 54-60.
14. Knapper S, Burnett AK, Littlewood T, Kell WJ, Agrawal S, et al. (2006) A phase 2 trial of the FLT3 inhibitor lestaurtinib (CEP701) as first line treatment for older patients with acute myeloid leukemia not considered fit for intenstive chemotherapy. Blood 108: 3262-3270.
15. Piloto O, Wright M, Brown P, Kim KT, Levis M, et al. (2007) Prolonged exposure to FLT3 inhibitors leads to resistance via activation of parallel signaling pathways. Blood 109: 1643-1652.
16. Zhou J, Bi C, Janakakumara JV, Liu SC, Chng WJ, et al. (2009) Enhanced activation of STAT pathways and overexpression of survivin confer resistance to FLT3 inhibitors and could be therapeutic targets in AML. Blood 113: 4052-4062.
17. Stölzel F, Steudel C, Oelschlägel U, Mohr B, Koch S, et al. (2010) Mechanisms of resistance against PKC412 in resistant FLT3-ITD positive human acute myeloid leukemia cells. Ann Hematol 89: 653-662.
18. Albert DH, Tapang P, Magoc TJ, Pease LJ, Reuter DR, et al. (2006) Preclinical activity of ABT-869: a multitargeted receptor tyrosine kinase inhibitor. Mol Cancer Ther 5: 995-1006.
19. Shankar DB, Li J, Tapang P, Owen J, Pease LJ, et al. (2007) ABT-869, a multitargeted receptor tyrosine kinase inhibitor: inhibition of FLT3 phosphorylation and signaling in acute myeloid leukemia. Blood 109: 3400-3408.
20. Ruggeri B, Singh J, Gingrich D, Angeles T, Albom M, et al. (2003) CEP-7055: a novel, orally active pan inhibitor of vascular endothelial growth factor receptor tyrosine kinases with potent antiangiogenic activity and antitumor efficacy in preclinical models. Cancer Res 63: 5978-5991.
21. Levis M, Allebach J, Tse KF, Zheng R, Baldwin BR, et al. (2002) A FLT3-targeted tyrosine kinase inhibitor is cytotoxic to leukemia cells in vitro and in vivo. Blood 99: 3885-91.
22. Weisberg E, Choi HG, Barrett R, Zhou W, Zhang J, et al. (2010) Discovery and characterization of novel mutant FLT3 kinase inhibitors. Mol Cancer Ther 9: 2468-2477.
23. Armstrong SA, Kung AL, Mabon ME, Silverman LB, Stam RW, et al. (2003) Validation of a therapeutic target identified by gene expression based classification. Cancer Cell 3: 173-183.
24. Shah NP, Nicoll JM, Nagar B, Gorre ME, Paquette RL, et al. (2002) Multiple BCR-ABL kinase domain mutations confer polyclonal resistance to the tyrosine kinase inhibitor imatinib (STI571) in chronic phase and blast crisis chronic myeloid leukemia. Cancer Cell 2: 117-125.
25. Cools J, Mentens N, Furet P, Fabbro D, Clark JJ, et al. (2004) Prediction of resistance to small molecule FLT3 inhibitors: implications for molecularly targeted therapy of acute leukemia. Cancer Res 64: 6385-6389.
26. Heidel F, Solem FK, Breitenbuecher F, Lipka DB, Kasper S, et al. (2006) Clinical resistance to the kinase inhibitor PKC412 in acute myeloid leukemia by mutation of Asn-676 in the FLT3 tyrosine kinase domain. Blood 107: 293-300.
27. Kelly LM, Liu Q, Kutok JL, Williams IR, Boulton CL, et al. (2002) FLT3 internal tandem duplication mutations associated with human acute myeloid leukemias induce myeloproliferative disease in a murine bone marrow transplant model. Blood 99: 310-318.
28. Von Bubnoff N, Engh RA, Aberg E, Sanger J, Peschel C, et al. (2009) FMS-like tyrosine kinase 3-internal tandem duplication tyrosine kinase inhibitors display a nonoverlapping profile of resistance mutations in vitro. Cancer Res 69: 3032-3041.
29. Ray A, Cowan-Jacob SW, Manley PW, Mestan J, Griffin JD, (2007) Identification of BCR-ABL point mutations conferring resistance to the Abl kinase inhibitor AMN107 (nilotinib) by a random mutagenesis study. Blood 109: 5011-5015.
30. Von Bubnoff N, Sanger J, Manley PW, Mestan J, Peschel C, et al. (2006) Bcr-Abl resistance screening predicts a limited spectrum of point mutations to be associated with clinical resistance to the Abl kinase inhibitor AMN107. Blood 108: 1328-1333.
31. Pratz KW, Cortes J, Roboz GJ, Rao N, Arowojolu O, et al. (2009) A pharmacodynamic study of the FLT3 inhibitor KW-2449 yields insight into the basis for clinical response. Blood 113: 3938-3946.
32. Siendones E, Barbarroja N, Torres LA, Buendia P, Velasco F, et al. (2007) Inhibition of Flt3-activating mutations does not prevent constitutive activation of ERK/Akt/STAT pathways in some AML cells: a possible cause for the limited effectiveness of monotherapy with small-molecule inhibitors. Hematol Oncol 25: 30-37.
33. Pratz KW, Sato T, Murphy KM, Stine A, Rajkhowa T, et al. (2010) FLT3-mutant allelic burden and clinical status are predictive of response to FLT3 inhibitors in AML. Blood 115: 1425-1432.
34. Martelli AM, Evangelisti C, Chiarini F, McCubrey JA, (2010) The phosphatidylinositol 3-kinase/Akt/mTOR signaling network as a therapeutic target in acute myelogenous leukemia patients. Oncotarget 1: 89-103.
35. Shi L, Wang S, Zangari M, Xu H, Cao TM, et al. (2010) Over-expression of CKS1B activates both MEK/ERK and JAK/STAT3 signaling pathways and promotes myeloma cell drug-resistance. Oncotarget 1: 22-33.
36. Chu SJ, Small D, (2009) Mechanisms of resistance to FLT3 inhibitors. Drug Resist Updates 12: 8-16.
37. Sato TKS, Burnett AK, White P, Levis M, (2009) Increased plasma FLT3 ligand levels following chemotherapy may interfere with the clinical efficacy of FLT3 inhibitors. Blood 114 Abstract 937.
38. Vora HH, Shukla SN, Brahambhatt BV, Mehta SH, Patel NA, et al. (2010) Clinical relevance of FLT3 receptor protein expression in Indian patients with acute leukemia. Asia Pac J Clin Oncol 6: 306-319.
39. Kuchenbauer F, Kern W, Schoch C, Kohlmann A, Hiddemann W, et al. (2005) Detailed analysis of FLT3 expression levels in acute myeloid leukemia. Haematologica 90: 1617-1625.
40. Kang HJ, Lee JW, Kho SH, Kim MJ, Seo YJ, et al. (2010) High transcript level of FLT3 associated with high risk of relapse in pediatric acute myeloid leukemia. J Korean Med Sci 25: 841-845.
41. Zhang Z, Stiegler AL, Boggon TJ, Kobayashi S, Halmos B, (2010) EGFR-mutated lung cancer: a paradigm of molecular oncology. Oncotarget 1: 497-514.
42. Jin G, Matsushita H, Asai S, Tsukamoto H, Ono R, et al. (2009) FLT3-ITD induces ara-C resistance in myeloid leukemic cells through the repression of the ENT1 expression. Biochem Biophys Res Commun 390: 1001-1006.
43. Levis M, Pham R, Smith BD, Small D, (2004) In vitro studies of a FLT3 inhibitor combined with chemotherapy: sequence of administration is important to achieve synergistic cytotoxic effects. Blood 104: 1145-1150.
44. Schittenhelm MM, Kampa KM, Yee KW, Heinrich MC, (2009) The FLT3 inhibitor tandutinib (formerly MLN518) has sequence-independent synergistic effects with cytarabine and daunorubicin. Cell Cycle 8: 2621-2630.